Fieber bei systemischem Lupus erythematodes: Krankheitsschub oder Infektion?

Lorenz, Hannes; Pieterse, L.; Rüter, T.; Lorenz, Fryderyk

doi:10.1007/s00393-020-00773-8

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of particularly high CRP levels is due to the development of anti-CRP antibody, except in cases with serositis. 1,8,9 A recent study found that, except in Asian populations, 10 PCT could not be used as an infection-related marker in SLE patients with fever. SLE patients with fever are usually sensitive to glucocorticoids and most respond well to even a moderate dose.…”

Section: Discussionmentioning

confidence: 99%

Tocilizumab therapy for persistent high-grade fever in systemic lupus erythematosus: two cases and a literature review

Chaoyi

Shrestha

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Tocilizumab (TCZ) is a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the interleukin (IL)-6 receptor. We report on two patients with persistent high-grade fever and systemic lupus erythematosus (SLE) who were treated with TCZ. Two female Chinese patients presented with SLE and high-grade fever, with raised inflammatory markers including C-reactive protein, erythrocyte sedimentation rate, and IL-6, but no signs of opportunistic infections. Their fever and other symptoms responded poorly to broad-spectrum antibiotics, antifungals, antivirals, and glucocorticoids. They were both treated with TCZ. Their body temperatures returned to normal after treatment with TCZ, and other symptoms, including arthralgia, gradually improved. Both patients were followed-up and their conditions remained steady to date. TCZ may thus be an alternative treatment for patients with SLE and persistent high-grade fever who fail to respond to initial antibiotics and high-dose glucocorticoids.

show abstract